Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07031011Phase 1Not Yet Recruiting

PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer

Role: lead

NCT03599375Phase 1Unknown

Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia

Role: lead

NCT03410368Phase 2Unknown

NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.

Role: lead

All 3 trials loaded